142 related articles for article (PubMed ID: 38448788)
1. Serum CXCL13 level is related to treatment response and predicts disease prognosis in Waldenström macroglobulinemia.
Chen J; Jia MN; Cai H; Li ZP; Li J; Zhou DB; Cao XX
Ann Hematol; 2024 Mar; ():. PubMed ID: 38448788
[TBL] [Abstract][Full Text] [Related]
2. The role of high serum CXCL13 level in Waldenström macroglobulinemia.
Wu YY; Cai H; Zhao AL; Zhang L; Zhou DB; Cao XX; Li J
Leuk Res; 2019 Jun; 81():50-55. PubMed ID: 31015152
[TBL] [Abstract][Full Text] [Related]
3. Real-world data on the survival outcome of patients with newly diagnosed Waldenström macroglobulinemia.
Cho JH; Shim JH; Yoon SE; Kim HJ; Kim SH; Ko YH; Lee ST; Kim K; Kim WS; Kim SJ
Korean J Intern Med; 2021 May; 36(3):668-678. PubMed ID: 32791817
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics and prognosis of patients with Waldenström macroglobulinemia and its comparison with the Pivotal study].
Tao Y; Wang S; Wang L; Wu M; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2021 Dec; 42(12):993-997. PubMed ID: 35045669
[No Abstract] [Full Text] [Related]
5. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease.
Han JH; Suh CH; Jung JY; Nam JY; Kwon JE; Yim H; Kim HA
Arthritis Res Ther; 2015 Sep; 17(1):260. PubMed ID: 26385705
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib-based chemotherapy for patients with Waldenström macroglobulinemia: a single-center experience.
Liu Z; Jiang S; Gu J; Liu H; Song G; Cao X
Ann Hematol; 2023 Jan; 102(1):167-174. PubMed ID: 36374339
[TBL] [Abstract][Full Text] [Related]
7. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation.
Ahmed S; Zhao Q; Hanel W; Qazilbash MH; Patel K; Narra R; Kansagra A; Iqbal M; Awan FT; Christian B; Jaglowski SM; Kharfan-Dabaja MA; Hamadani M; Epperla N
Hematol Oncol; 2022 Feb; 40(1):48-56. PubMed ID: 34763367
[TBL] [Abstract][Full Text] [Related]
8. Circulating low CD4
Cao X; Kong YL; Wang L; Liang JH; Xia Y; Zhu HY; Fan L; Jiang SH; Liu H; Li JY; Xu W
Ann Hematol; 2021 Apr; 100(4):995-1002. PubMed ID: 33651193
[TBL] [Abstract][Full Text] [Related]
9. Circulating Soluble Receptor Activator of Nuclear Factor Kappa B Ligand and C-C Motif Ligand 3 Correlate With Survival in Patients With Waldenström Macroglobulinemia.
Eleutherakis-Papaiakovou E; Kastritis E; Gavriatopoulou M; Christoulas D; Roussou M; Ntanasis-Stathopoulos I; Kanellias N; Papatheodorou A; Dimopoulos MA; Terpos E
Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):431-437. PubMed ID: 29685422
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs.
Bugatti S; Manzo A; Benaglio F; Klersy C; Vitolo B; Todoerti M; Sakellariou G; Montecucco C; Caporali R
Arthritis Res Ther; 2012 Feb; 14(1):R34. PubMed ID: 22336440
[TBL] [Abstract][Full Text] [Related]
11. A role for CXCL13 (BCA-1) in pregnancy and intra-amniotic infection/inflammation.
Nhan-Chang CL; Romero R; Kusanovic JP; Gotsch F; Edwin SS; Erez O; Mittal P; Kim CJ; Kim MJ; Espinoza J; Friel LA; Vaisbuch E; Than NG; Mazaki-Tovi S; Hassan SS
J Matern Fetal Neonatal Med; 2008 Nov; 21(11):763-75. PubMed ID: 19031272
[TBL] [Abstract][Full Text] [Related]
12. Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.
Treon SP; Tripsas C; Hanzis C; Ioakimidis L; Patterson CJ; Manning RJ; Sheehy P; Turnbull B; Hunter ZR
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):433-7. PubMed ID: 23084402
[TBL] [Abstract][Full Text] [Related]
13. Deepening of response after completing rituximab-containing therapy in patients with Waldenstrom macroglobulinemia.
Castillo JJ; Gustine JN; Keezer A; Meid K; Flynn CA; Dubeau TE; Chan G; Chen J; Demos MG; Guerrera ML; Jimenez C; Kofides A; Liu X; Munshi M; Tsakmaklis N; Patterson CJ; Xu L; Yang G; Hunter ZR; Treon SP
Am J Hematol; 2020 Apr; 95(4):372-378. PubMed ID: 31868242
[TBL] [Abstract][Full Text] [Related]
14. The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients.
Kim SJ; Ryu KJ; Hong M; Ko YH; Kim WS
J Hematol Oncol; 2015 May; 8():49. PubMed ID: 25966773
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and response to fludarabine therapy in patients with Waldenström macroglobulinemia: results of United States intergroup trial (Southwest Oncology Group S9003).
Dhodapkar MV; Jacobson JL; Gertz MA; Rivkin SE; Roodman GD; Tuscano JM; Shurafa M; Kyle RA; Crowley JJ; Barlogie B
Blood; 2001 Jul; 98(1):41-8. PubMed ID: 11418461
[TBL] [Abstract][Full Text] [Related]
16. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia.
Leleu X; Moreau AS; Weller E; Roccaro AM; Coiteux V; Manning R; Nelson M; Leduc R; Robu D; Dupire S; Hatjiharissi E; Burwick N; Darre S; Hennache B; Treon SP; Facon T; Gertz MA; Ghobrial IM
Leuk Lymphoma; 2008 Jun; 49(6):1104-7. PubMed ID: 18452095
[TBL] [Abstract][Full Text] [Related]
17. CXCL13 and CCL11 Serum Levels and Lymphoma and Disease Activity in Primary Sjögren's Syndrome.
Nocturne G; Seror R; Fogel O; Belkhir R; Boudaoud S; Saraux A; Larroche C; Le Guern V; Gottenberg JE; Mariette X
Arthritis Rheumatol; 2015 Dec; 67(12):3226-33. PubMed ID: 26359802
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of CXCL13 are elevated in active multiple sclerosis.
Festa ED; Hankiewicz K; Kim S; Skurnick J; Wolansky LJ; Cook SD; Cadavid D
Mult Scler; 2009 Nov; 15(11):1271-9. PubMed ID: 19805441
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and biological characteristics of non-IgM lymphoplasmacytic lymphoma].
Yu Y; Xiong WJ; Chen JW; Jiao Y; Yan YT; Wang Q; Zou DH; Liu W; Liu HM; Lyu R; Qiu LG; Yi SH
Zhonghua Xue Ye Xue Za Zhi; 2022 Jul; 43(7):568-574. PubMed ID: 36709134
[No Abstract] [Full Text] [Related]
20. Minimal residual disease status improved the response evaluation in patients with Waldenström's macroglobulinemia.
Xiong W; Wang Z; Wang T; Yu Y; Huang Y; Sun H; Chen J; Lyu R; Wang H; Yan Y; Wang Q; Liu W; An G; Sui W; Huang W; Zou D; Xiao Z; Wang J; Ouyang G; Qiu L; Yi S
Front Immunol; 2023; 14():1171539. PubMed ID: 37234167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
